Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07171489 · ClinicalTrials.gov registry record · NA
Efficacy of a Wearable Noninvasive Neuromodulation Device
A NA study, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07171489: Recruiting NA study, sponsored by University of Michigan.
NCT07171489 is a NA study that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07171489, a NA study, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment intervention vs. a sham control intervention on NBD symptoms in patients with SCI. The study hypotheses: * The proposed TNM treatment at a leg point will reduce NBD symptoms between baseline and post-therapy, when compared to the sham-TNM treatment. * The therapeutic effect of TNM to improve the NBD symptoms is associated with improvement of the autonomic function in SCI patients.
Primary Outcome
The scoring the degree of NBD symptoms and bowel routines, including frequency of bowel movements (0, 1 or 6 points), headache, perspiration or discomfort before or during defecation (0 or 2 points), medications for constipation (0, to 4 points), time used for each defecation (0, 3 or 7 points), frequency of digital stimulation or evacuation (0, 6 points), frequency of fecal incontinence (0, 6, 7 or13 points), medication for fecal incontinence (0, or 4 points), flatus incontinence (0 pr 2 points
Interventions
- DEVICE TNM at a sham-point (AccelBand) - randomized arm
- DEVICE TNM at a leg point (AccelBand)- randomized arm
- DEVICE TNM at a leg point (AccelBand)- open-label
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-11 |
| Phase | NA |
What NCT07171489 shows while recruiting
NCT07171489 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which TNM at a sham-point (AccelBand) - randomized arm is the first listed.
NCT07171489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07171489 about?
NCT07171489 is a clinical study titled "Efficacy of a Wearable Noninvasive Neuromodulation Device". The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment interven...
What is the current status of trial NCT07171489?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-07. Estimated completion is 2029-11.
What interventions are being tested in trial NCT07171489?
The interventions under investigation include: TNM at a sham-point (AccelBand) - randomized arm (DEVICE), TNM at a leg point (AccelBand)- randomized arm (DEVICE), TNM at a leg point (AccelBand)- open-label (DEVICE).
Who is sponsoring clinical trial NCT07171489?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07171489's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia